Overview

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Status:
Completed

Trial end date:
2020-05-01

Target enrollment:

Participant gender:

Summary

In this multicenter study, patients with resectable pancreatic carcinoma will be treated with (a) surgery followed by 6 cycles gemcitabine or (b) 4-6 cycles FOLFIRINOX followed by surgery followed by 4-6 cycles FOLFIRINOX. The overall survival between both therapies will be compared as well as other parameters.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Krankenhaus Nordwest

Treatments:

Fluorouracil
Gemcitabine
Irinotecan
Oxaliplatin